Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):610–614. doi: 10.1128/aac.35.4.610

Pharmacokinetics of 2',3'-dideoxyinosine (BMY-40900), a new anti-human immunodeficiency virus agent, after administration of single intravenous doses to beagle dogs.

S Kaul 1, C A Knupp 1, K A Dandekar 1, K A Pittman 1, R H Barbhaiya 1
PMCID: PMC245067  PMID: 1906259

Abstract

The pharmacokinetics of 2',3'-dideoxyinosine (ddI) were investigated in four adult male beagle dogs that received 15-min infusions of 20-, 50-, and 100-mg/kg doses in a randomized crossover study design. Plasma and urine samples were collected for 10 and 24 h, respectively, and assayed for ddI by high-performance liquid chromatographic methods. The mean maximum concentrations of drug in plasma at the end of 15-min infusions for the 20-, 50-, and 100-mg/kg doses were 33.3, 90.0, and 202 micrograms/ml, respectively. Area under the concentration-time curve data deviated significantly from linearity. The mean total clearance for the low dose (250 ml/min) was significantly greater than that for the high dose (190 ml/min). Renal clearance, which averaged between 98 and 116 ml/min, was dose independent. Renal clearance implied that nonrenal clearance decreased at the high dose (92 ml/min) when compared with that of the low dose (134 ml/min). The average urinary recovery of ddI for the high dose (51.2% of dose) was significantly greater than that for the low dose (45.8%). The volume of distribution at steady state averaged between 7.6 and 10.5 liters and decreased with increasing dose; however, it was not statistically significant. The mean half-life and mean residence time were invariant with respect to dose and averaged between 0.94 and 1.07 h and 0.61 and 0.71 h, respectively. In this dose range, ddI pharmacokinetics are dose dependent.

Full text

PDF
610

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahluwalia G., Cooney D. A., Mitsuya H., Fridland A., Flora K. P., Hao Z., Dalal M., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987 Nov 15;36(22):3797–3800. doi: 10.1016/0006-2952(87)90440-0. [DOI] [PubMed] [Google Scholar]
  2. Campbell D. B., Ings R. M. New approaches to the use of pharmacokinetics in toxicology and drug development. Hum Toxicol. 1988 Sep;7(5):469–479. doi: 10.1177/096032718800700515. [DOI] [PubMed] [Google Scholar]
  3. Chan K. K., Gibaldi M. Estimation of statistical moments and steady-state volume of distribution for a drug given by intravenous infusion. J Pharmacokinet Biopharm. 1982 Oct;10(5):551–558. doi: 10.1007/BF01059037. [DOI] [PubMed] [Google Scholar]
  4. Gibaldi M., Levy G., McNamara P. J. Effect of plasma protein and tissue binding on the biologic half-life of drugs. Clin Pharmacol Ther. 1978 Jul;24(1):1–4. doi: 10.1002/cpt19782411. [DOI] [PubMed] [Google Scholar]
  5. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1911–1915. doi: 10.1073/pnas.83.6.1911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Plagemann P. G., Woffendin C. Permeation and salvage of dideoxyadenosine in mammalian cells. Mol Pharmacol. 1989 Jul;36(1):185–192. [PubMed] [Google Scholar]
  7. Riegelman S., Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980 Oct;8(5):509–534. doi: 10.1007/BF01059549. [DOI] [PubMed] [Google Scholar]
  8. Russell J. W., Klunk L. J. Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Biochem Pharmacol. 1989 May 1;38(9):1385–1388. doi: 10.1016/0006-2952(89)90176-7. [DOI] [PubMed] [Google Scholar]
  9. Stoeckler J. D., Cambor C., Parks R. E., Jr Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates. Biochemistry. 1980 Jan 8;19(1):102–107. doi: 10.1021/bi00542a016. [DOI] [PubMed] [Google Scholar]
  10. Yarchoan R., Mitsuya H., Thomas R. V., Pluda J. M., Hartman N. R., Perno C. F., Marczyk K. S., Allain J. P., Johns D. G., Broder S. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science. 1989 Jul 28;245(4916):412–415. doi: 10.1126/science.2502840. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES